These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32162562)

  • 1. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B.
    Hadziyannis E; Hadziyannis S
    Expert Rev Gastroenterol Hepatol; 2020 Apr; 14(4):243-251. PubMed ID: 32162562
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
    Tout I; Lampertico P; Berg T; Asselah T
    Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero E; Del Arco RTS; Peña-Asensio J; de Villalobos ES; Míquel J; Larrubia JR
    World J Gastroenterol; 2018 May; 24(17):1825-1838. PubMed ID: 29740199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.
    van Bömmel F; Berg T
    Hepatol Commun; 2021 Oct; 5(10):1632-1648. PubMed ID: 34558833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we stop nucleoside analogues before HBsAg loss?
    Papatheodoridi M; Papatheodoridis G
    J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
    Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
    Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
    Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
    Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs.
    Li T; Liu F; Zhang L; Ye Q; Fan X; Xue Y; Wang L
    Saudi J Gastroenterol; 2018; 24(1):30-36. PubMed ID: 29451182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis.
    Liu Y; Jia M; Wu S; Jiang W; Feng Y
    Int J Infect Dis; 2019 Sep; 86():201-207. PubMed ID: 31394205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
    Yu SL; Guo CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.